Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.008 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.008 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.008 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.008 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.008 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.008 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.008 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.008 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.008 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.005 | 0.3805 | 0.3805 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.008 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.004 | 0.1841 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.008 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.004 | 0.1964 | 0.0151 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.008 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.008 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0071 | 0.8159 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.008 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.008 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.008 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0071 | 0.8159 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0 | 0.5 |
Treponema pallidum | flavodoxin | 0.0031 | 0 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.008 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.008 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.008 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.008 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.005 | 0.3805 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.008 | 1 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.0071 | 0.8159 | 0.8159 |
Giardia lamblia | Hypothetical protein | 0.0071 | 0.8159 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.004 | 0.1841 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0071 | 0.8159 | 0.8159 |
Leishmania major | p450 reductase, putative | 0.008 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.005 | 0.3805 | 0.3805 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.005 | 0.3805 | 0.2407 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against CEM tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against L1210 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against B16 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against Molt-4 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against WIL2 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against WI38 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against K562 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against HL-60 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against H596 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against H292 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against MCF-7 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against A549 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
Cytotoxicity (functional) | 0 | Cytotoxicity of the compound was evaluated against NIH3T3 tumor cell lines ; Inactive | ChEMBL. | 10743954 |
IC50 (functional) | > 50 uM | In vitro test for antitumor activity against human Jurkat cell line using a formazan dye (MTT) conversion assay. | ChEMBL. | 10743954 |
IC50 (functional) | > 50 uM | In vitro test for antitumor activity against human Jurkat cell line using a formazan dye (MTT) conversion assay. | ChEMBL. | 10743954 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.